Spots Global Cancer Trial Database for A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer
Official Title: A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer in Patients Who Have Failed Therapy With an Irinotecan and Fluoropyrimidine Regimen
Study ID: NCT00500292
Study Description
Brief Summary: The purpose of this study is to determine whether treatment with ZACTIMA (vandetanib) in combination with FOLFOX is more effective than FOLFOX alone for colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine containing regimen.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Lille Cedex, , France
Research Site, Toulouse Cedex 9, , France
Research Site, Budapest, , Hungary
Research Site, Debrecen, , Hungary
Research Site, Szeged, , Hungary
Research Site, Seoul, , Korea, Republic of
Research Site, Bratislava, , Slovakia
Research Site, Poprad, , Slovakia
Research Site, Trnava, , Slovakia
Research Site, Zilina, , Slovakia
Research Site, Hospitalet deLlobregat, , Spain
Research Site, Oviedo, , Spain
Research Site, Santander, , Spain
Research Site, Taipei, , Taiwan
Research Site, Tao-Yuan, , Taiwan
Contact Details
Name: Clinical Sciences & Operations
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
